Epidemic and pandemic viral infections: impact on tuberculosis and the lung. A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN) and members# of ESCMID Study Group for Mycobacterial Infections (ESGMYC). by Min Ong, CW et al.
Early View 
Task force report 
Epidemic and pandemic viral infections: impact 
on tuberculosis and the lung. A consensus by the 
World Association for Infectious Diseases and 
Immunological Disorders (WAidid), Global 
Tuberculosis Network (GTN) and members# of 
ESCMID Study Group for Mycobacterial Infections 
(ESGMYC) 
Catherine Wei Min Ong, Giovanni Battista Migliori, Mario Raviglione, Gavin MacGregor-Skinner, 
Giovanni Sotgiu,  Jan-Willem Alffenaar, Simon Tiberi, Cornelia Adlhoch, Tonino Alonzi, Sophia 
Archuleta, Sergio Brusin, Emmanuelle Cambau, Maria Rosaria Capobianchi, Concetta Castilletti, 
Rosella Centis, Daniela M. Cirillo,  Lia D'Ambrosio, Giovanni Delogu, Susanna M.R. Esposito, Jose 
Figueroa, Jon S. Friedland, Benjamin Ho Choon Heng, Giuseppe Ippolito, Mateja Jankovic, Hannah 
Yejin Kim, Senia Rosales Klintz, Csaba Ködmön, Eleonora Lalle, Yee Sin Leo,  Chi-Chiu Leung, 
Anne-Grete Märtson, Mario Melazzini, Saeid Najafi Fard, Pasi Penttinen, Linda Petrone, Elisa 
Petruccioli, Emanuele Pontali, Laura Saderi, Miguel Santin, Antonio Spanevello, Reinout van Crevel, 
Marieke J. van der Werf, Dina Visca, Miguel Viveiros, Jean Pierre Zellweger, Alimuddin Zumla, 
Delia Goletti.
Please cite this article as: Min Ong CW, Migliori GB, Raviglione M, MacGregor-Skinner G, et
al. Epidemic and pandemic viral infections: impact on tuberculosis and the lung. A consensus 
by the World Association for Infectious Diseases and Immunological Disorders (WAidid), 
Global Tuberculosis Network (GTN) and members# of ESCMID Study Group for 
Mycobacterial Infections (ESGMYC). Eur Respir J 2020; in press (https://
doi.org/10.1183/13993003.01727-2020).
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is 
published here in its accepted form prior to copyediting and typesetting by our production team. After 
these production processes are complete and the authors have approved the resulting proofs, the article 
will move to the latest issue of the ERJ online. 
Copyright ©ERS 2020. This article is open access and distributed under the terms of the 
Creative Commons Attribution Non-Commercial Licence 4.0. 
Epidemic and pandemic viral infections: impact on tuberculosis and the lung.  
A consensus by the World Association for Infectious Diseases and Immunological Disorders 
(WAidid), Global Tuberculosis Network (GTN) and members
# 
of ESCMID Study Group for
Mycobacterial Infections (ESGMYC). 
Authors: 
Catherine Wei Min Ong
1,2#
*, Giovanni Battista Migliori
3
*, Mario Raviglione
4,5
, Gavin MacGregor-
Skinner
6
, Giovanni Sotgiu
7
,  Jan-Willem Alffenaar
8,9,10#
, Simon Tiberi
11,12#
, Cornelia Adlhoch
13˄
, 
Tonino Alonzi
14
, Sophia Archuleta
1
, Sergio Brusin
13˄
, Emmanuelle Cambau
15#
, Maria Rosaria 
Capobianchi
16
, Concetta Castilletti
16
, Rosella Centis
3
, Daniela M. Cirillo
17#
,  Lia D'Ambrosio
18
, 
Giovanni Delogu
19,20#
, Susanna M.R. Esposito
21
, Jose Figueroa
22
, Jon S. Friedland
23#
, Benjamin Ho 
Choon Heng
24
, Giuseppe Ippolito
25
, Mateja Jankovic
26#
, Hannah Yejin Kim
8,9,10
, Senia Rosales 
Klintz
13˄
, Csaba Ködmön
13˄
, Eleonora Lalle
16
, Yee Sin Leo
27
,  Chi-Chiu Leung
28
, Anne-Grete 
Märtson
29
, Mario Melazzini
30
, Saeid Najafi Fard
14
, Pasi Penttinen
13˄
, Linda Petrone
14
, Elisa 
Petruccioli
14
, Emanuele Pontali
31
, Laura Saderi
7
, Miguel Santin
32,33#
, Antonio Spanevello
34,35
, 
Reinout van Crevel
36,37#
, Marieke J. van der Werf
13˄
, Dina Visca
34,35
, Miguel Viveiros
38#
, Jean 
Pierre Zellweger
39
, Alimuddin Zumla
40
, Delia Goletti
14#
.       
*Equally contributed
˄ The European Centre for Disease Prevention and Control Public Health Emergency (ECDC 
PHE) team co-Authors did not participate to the Delphi process and development of Table 4 
Affiliations: 
1. Department of Medicine, Yong Loo Lin School of Medicine, National University of
Singapore, Singapore
2. Institute for Health Innovation & Technology (iHealthtech), National University of
Singapore, Singapore
3. Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici
Maugeri IRCCS, Tradate, Italy
4. Centre for Multidisciplinary Research in Health Science, University of Milan, Milan, Italy
5. Global Studies Institute, University of Geneva, Geneva, Switzerland
6. Department of Public Health Sciences, Penn State College of Medicine, Hershey,
Pennsylvania, USA
7. Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and
Experimental Sciences, University of Sassari, Sassari, Italy 
8. University of Sydney, Sydney Pharmacy School, Sydney, New South Wales, Australia 
9. Westmead Hospital, Sydney, Australia 
10. Marie Bashir Institute of Infectious Diseases and Biosecurity, University of Sydney, 
Sydney, Australia. 
11.  Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary 
University of London, London, United Kingdom. 
12.  Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, United   
Kingdom 
13. Public Health Emergency team, European Centre for Disease Prevention and Control, 
Stockholm, Sweden 
14. Translational Research Unit, Epidemiology and Preclinical Research Department,  
“L. Spallanzani” National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy 
15.  APHP-Lariboisiere, Bacteriologie, laboratory associated to the National reference center for 
mycobacteria; IAME UMR1137, INSERM, University of Paris, Paris, France 
16. Laboratory of Virology, Epidemiology and Preclinical Research Department, “L. 
Spallanzani” National Institute for Infectious Diseases (INMI), IRCCS,  Rome, Italy 
17. Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy 
18. Public Health Consulting Group, Lugano, Switzerland 
19. Università Cattolica Sacro Cuore, Roma, Italy 
20. Mater Olbia Hospital, Olbia, Italy 
21. Pediatric Clinic, Pietro Barilla Children’s Hospital, University of Parma, Parma, Italy 
22. National Health Service (NHS), London, United Kingdom 
23. St George’s, University of London, London, United Kingdom 
24. Tuberculosis Control Unit, Department of Respiratory and Critical Care Medicine, Tan 
Tock Seng Hospital, Singapore 
25. Scientific Direction, “L. Spallanzani” National Institute for Infectious Diseases (INMI), 
IRCCS, Rome, Italy 
26. University of Zagreb, School of Medicine, Clinic for Respiratory Diseases, University 
Hospital Center Zagreb, Zagreb, Croatia 
27. National Centre for Infectious Diseases, Singapore 
28. Hong Kong Tuberculosis, Chest and Heart Diseases Association, Wanchai, Hong Kong, 
China   
29. University of Groningen, University Medical  Center Groningen, Department of Clinical 
Pharmacy and Pharmacology, Groningen, the Netherlands 
30. Scientific Direction, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy 
31. Department of Infectious Diseases, Galliera Hospital, Genova, Italy 
32. Department of Infectious Diseases, Bellvitge University Hospital-Bellvitge Biomedical 
Research Institute (IDIBELL), L’Hospitalet de Llobregat, Spain 
33. Department of Clinical Science, University of Barcelona, L'Hospitalet de Llobregat, Spain. 
34. Division of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, 
Italy 
35. Department of Medicine and Surgery, Respiratory Diseases, University of Insubria, Varese-
Como, Italy 
36. Radboudumc Center for Infectious Diseases, Radboud Institute for Health Sciences, 
Radboudumc, Nijmegen, the Netherlands 
37. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 
University of Oxford, Oxford, United Kingdom 
38. Global Health and Tropical Medicine, Institute of Hygiene and Tropical Medicine, NOVA 
University of Lisbon, Lisbon, Portugal 
39. TB Competence Centre, Swiss Lung Association, Berne, Switzerland 
40. Department of Infection, Division of Infection and Immunity, University College London 
and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, 
United Kingdom 
 
 
Corresponding Author: 
Delia Goletti, Translational Research Unit, Epidemiology and Preclinical Research Department,  
“L. Spallanzani” National Institute for Infectious Diseases (INMI), IRCCS, Via Portuense 292, 
00149, Rome, Italy. Email: delia.goletti@inmi.it 
 
Co-corresponding Author:  
Giovanni Battista Migliori, Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti 
Clinici Scientifici Maugeri IRCCS, Via Roncaccio 16, Tradate, Varese, 21049, Italy. E-mail: 
giovannibattista.migliori@icsmaugeri.it 
 
Key words: viral infections, lung, TB, COVID-19, immunology, diagnosis, treatment, prevention, 
infection control, work place safety 
 
Running title: Epidemics, pandemic viral infections and interactions with TB and the lung 
 
Take-home message: In this consensus we describe the effects of the viral infections resulting in 
epidemics and pandemics affecting the lung (MERS, SARS, HIV, influenza A (H1N1)pdm/09 and 
COVID-19) and their interactions with tuberculosis, the top infectious disease killer. 
 
  
Abstract 
Major epidemics including some that qualify as pandemics, such as Severe Acute Respiratory Syndrome 
(SARS), Middle-Eastern Respiratory Syndrome (MERS), Human Immunodeficiency Virus, pandemic 
H1N1/09 and most recently COVID-19 affect the lung.  Tuberculosis (TB) remains the top infectious disease 
killer but apart from the TB-HIV syndemic, little is known regarding the interaction of viral epidemics and 
pandemics with TB.  The aim of this consensus-based document is to describe the effects of the viral 
infections resulting in epidemics and pandemics that affect the lung (MERS, SARS, HIV, influenza A 
(H1N1)pdm/09 and COVID-19) and their interactions with TB.  A search of the scientific literature was 
performed. A writing committee of international experts including the European Centre for Disease 
Prevention and Control Public Health Emergency (ECDC PHE) team, the World Association for Infectious 
Diseases and Immunological Disorders (WAidid), the Global Tuberculosis Network (GTN) and members of 
ESCMID Study Group for Mycobacterial Infections (ESGMYC) was established.   Consensus was achieved 
after multiple rounds of revisions between the writing committee and a larger expert group. A Delphi process 
involving the core group of authors, excluding the ECDC PHE team identified the areas requiring 
review/consensus, followed by a second round to refine the definitive consensus elements.  The 
epidemiology, immunology of these viral infections and their interactions with TB are discussed with 
implications on diagnosis, treatment and prevention of airborne infections (infection control, viral 
containment and workplace safety).  This consensus document represents a rapid and comprehensive 
summary on what is known on the topic.  
1. Introduction.  
The 21st century has been marked by major epidemics, including some that qualify as pandemics,  
caused by old diseases such as cholera, plague, and yellow fever as well as emerging ones such as Severe 
Acute Respiratory Syndrome (SARS), Ebola, Zika, Middle-Eastern Respiratory Syndrome (MERS), 
Human Immunodeficiency Virus (HIV, although technically endemic), influenza A (H1N1)pdm/09 and 
most recently COVID-19.  Several of these viruses affect the lung.   Tuberculosis (TB) remains the top 
infectious disease killer caused by a single organism responsible for 1.5 million deaths in 2018 [1].  
Apart from the TB-HIV syndemic, little is known regarding the interaction of other viral epidemics with 
TB.  This consensus-based document describes the effects of the main viral epidemics which 
predominately affect the lungs or cause systemic immunosuppression (MERS, SARS, HIV, influenza 
A(H1N1)pdm09 and COVID-19), and their interactions with TB at a diagnostic, treatment and public 
health level.  It is fruit of a collaborative project involving the ECDC PHE team (European Centre for 
Disease Prevention and Control, Public Health Emergency), the World Association for Infectious 
Diseases and Immunological Disorders (WAidid), the GTN (Global Tuberculosis Network) and 
members of ESCMID Study Group for Mycobacterial Infections (ESGMYC). 
 
2. Methods 
We did a rapid and non-systematic search of the literature using the key-words ‘COVID-19’, 
‘tuberculosis’, ‘viral infection’, ‘HIV infection’, ‘SARS’, ‘lung’, ‘immunology’, “diagnosis’, ‘prevention’, 
‘infection control’, ‘workplace’ to identify a minimum set of references from an electronic database 
(PUBMED), existing guidelines on TB, viral diseases, airborne diseases, and grey literature from their 
inception until 29 April 2020. Guidelines were retrieved from the websites of the main international health-
related centres, whereas grey literature was accessed using Google search engine.    
A writing committee composed of international experts was established, including the ECDC PHE team, 
WAidid, GTN and ESGMYC. 
Consensus on the content was achieved after multiple rounds of revisions between the writing committee and 
the larger group of experts [2]. 
A Delphi process involving the core group of Authors, excluding the ECDC PHE team, identified the areas 
requiring review/consensus, followed by a second round to refine the definitive consensus elements.  
As this review is not aimed at duplicating World Health Organization (WHO), ECDC and other existing 
guidelines, the GRADE methodology was not used, and no formal recommendations are provided. The 
available information on prevention, diagnosis, and treatment of TB and pulmonary viral diseases was 
selected by the experts and summarised and country examples were provided to critically discuss the public 
health response. 
  
3.  Viral diseases of the lung  
3.1  Epidemiology. 
Viral respiratory infections are a major public health concern due to the capacity of viruses to spread 
from person to person directly via aerosols/droplet nuclei, small droplets or virus laden secretions from 
larger droplets; or indirectly by contact with contaminated surfaces [3]. Large respiratory droplets are 
generated primarily during coughing, sneezing and talking, and during procedures such as suctioning and 
bronchoscopy, which can also generate droplet nuclei. Transmission occurs when droplets containing micro-
organisms from an infected person are expelled a short distance through the air and deposited on another 
individual’s conjunctivae, nasal mucosa or mouth. Large droplets fall quickly onto surfaces close to the 
infected person, increasing the risk of contact transmission.  Moreover, viral infections can also be 
transmitted via aerosol particles of small size (<5-10 µm) which may be infectious at a distance of several 
meters [4-7].  Recent evidence suggests the SARS-CoV-2 virus may be present in exhaled air while talking 
and breathing [8], being detected for several hours [9] on different surfaces. 
 
Respiratory infections can be classified by the causative virus such as influenza or clinically according to the 
clinical syndrome. Symptoms may include fever, non-productive cough, coryza, sneezing, dyspnoea, 
myalgia, fatigue and non-exudative pharyngitis [10]. 
 
The clinical spectrum can encompass asymptomatic infection, upper respiratory tract infection, and lower 
respiratory tract infection that can result in pneumonia or acute respiratory distress [11], and systemic 
infection [12]. 
 
The severity of viral respiratory illness varies widely, and severe disease is more likely in older patients with 
or without comorbidities. Infants may have more severe disease for some organisms. Morbidity may result 
directly from viral infection or may be due to exacerbation of other chronic medical conditions, or bacterial 
super-infection [13, 14]. 
 
The spread of respiratory virus infections varies between countries and regions, depending on differences in 
population, geography, climate, immunization coverage, and socioeconomic status [15-17].  
 
3.2  Immunology. 
The first line of defence against respiratory viral infections includes intrinsic defences such as 
mucous and antiviral peptides. When these are circumvented, viruses enter the epithelial cells by recognizing 
viral components via Toll-like receptors (TLRs) and intracellular receptors [18] (Figure 1), and initiate the 
inflammatory response. Innate cells such as dendritic cells, alveolar macrophages, natural killer cells and 
neutrophils are recruited. All these cells promote an anti-viral response and are important for the 
establishment of adaptive responses. Concurrently, these inflammatory cells may be important in driving 
innate immune-mediated tissue damage, a process which also occurs in tuberculosis [19]. 
 
T-cells contribute to the generation of the B-cell response, and cell-mediated immunity leading to viral 
clearance. In particular, B-cells produce antibodies that may neutralise the respiratory viruses directly by 
binding to viral surface proteins or activating the complement cascade (Figure 1)[20, 21]. Viral clearance is 
also mediated by CD8+-specific T-cells with cytolytic activity. Protective anti-viral T-cell response is a Th1 
response mainly mediated through interferon (IFN)-γ production [22-25]. Moreover, to prevent lung tissue 
damage, all these responses are finely modulated; regulatory mechanisms adopted by T-cells such as 
cytokine secretion, upregulation of inhibitory receptors [26], or expansion of the T- cell regulatory subset 
lead to a balance between tissue damage and clearance of the virus.  The immune systems of neonates, 
infants, children and adults are different, in their composition and functional responsiveness to infectious 
diseases [27, 28].  
 
Regarding the response to Mycobacterium tuberculosis (Mtb), after mycobacterial dissemination to the 
lymph nodes, dendritic cells present bacterial antigens to T-cells and prime them [29, 30]. Priming occurs 
around 10 days post-infection in the mediastinal lymph nodes and is followed by generation of effector T-
cells [31], and Th1 CD4+ T-cells that lead to the formation of granulomas. Granulomas are organized 
structures where T-cells and B-cells surround innate immune cells (macrophages and neutrophils) with a 
fibrotic capsule to generate a hypoxic environment to prevent Mtb growth [32], with hypoxia potentially 
worsening tissue destruction in TB [33].  CD4 Th1 host responses are crucial [34], especially at the 
beginning for TB control [35, 36]. Regarding the CD8 T-cell component, mouse studies have revealed a 
relatively smaller role of CD8+ T-cells in protection against Mtb infection [37], and an even  smaller 
contribution of B-cells and humoral immunity [38]. Differently, in human studies Mtb-specific CD8 T-cells 
have been associated with active TB [39-44], both in HIV-uninfected and -infected patients [35, 42, 45], and 
in response to recent infections [43, 44].  Increased CD8 T-cell responses is associated with Mtb load and 
longitudinal studies have shown a decrease of this CD8 T-cell response during anti-TB treatment [39, 40]. It 
has been shown that they are differently modulated over the course of TB disease suggesting a role in the TB 
pathogenesis that is not yet fully elucidated [46-48]. 
 
Bacille-Calmette Guerin (BCG) vaccination as a potential intervention against COVID-19  
BCG, the current vaccine against TB has important protective effects against other infections. In 
randomised trials, BCG reduced infant mortality by around 40% [49], and respiratory infections other than 
TB by 70% in adolescents [50]. These ‘non-specific effects’ of BCG-vaccination are explained by epigenetic 
and metabolic reprogramming of innate immune cells, a process termed ‘trained immunity’ [51].  Clinical 
evidence suggests that BCG may protect against viruses [52], and BCG-vaccinated healthy adults re-
challenged with the live yellow fever vaccine showed improved anti-viral immunity and decreased viral 
loads [53]. In mice, BCG-vaccination protects against influenza A, lowering viral replication and lung injury 
[54, 55].  
 
A recent ecological analysis has suggested that BCG-vaccination may also protect against COVID-19 [56]. 
Countries without universal policies of BCG-vaccination (Italy, Netherlands, USA) seem more severely 
affected by COVID-19 compared to countries with universal BCG policies. However, such ecological 
studies that relate country aggregate and individual data should be interpreted with caution. Also, COVID-19 
showed a recent increase since publication in low- and middle-income countries and may still be under-
reported, confounders such as age were not taken into account, and variable BCG policies over time affect 
individual BCG coverage [57-59]. Several large RCTs currently evaluating the effect of BCG-vaccination 
against COVID-19 in thousands of health care workers and elderly, in the Netherlands, Australia and other 
countries, will provide evidence to support or refute BCG as a cheap and rapidly scalable preventive measure 
against COVID-19 and other viral respiratory infections. 
 
3.3  Influenza H1N1 and lung disease 
 
The two most serious impacts of influenza virus on the lung are the development of pneumonia and 
exacerbation of pre-existing pulmonary disease [60]. Such events seem rare and variable during most 
seasonal influenza periods but may be more frequent and severe in pandemics.  During the 2018-2019 
season, there was an estimated 32 million cases of influenza resulting in 32,000 deaths in the USA [61].  
H1N1, the virus behind the 1918 and 2009 pandemics, appears to cause more rapid and severe pneumonia 
than other strains, with higher rates of bacterial super-infection [62].  H1N1 also affects the paediatric 
population [63, 64]. 
 
Primary viral pneumonia is characterised by rapid onset of non-productive cough, headache, myalgias, 
dyspnoea, tachypnea, hypoxia and ground-glass opacities on CT scans. Secondary bacterial pneumonia, 
which may occur concurrently or following the development of viral pneumonia, is a frequent complication. 
Bacterial super-infection occurs through direct damage of the respiratory epithelium with modification of 
local and systemic immune defense.  Bacterial super-infection, mainly due to Staphylococcus aureus and 
Streptococcus pneumoniae [65], is reported in 20-47% of influenza patients admitted to intensive care units 
(ICU). Its global prevalence varies between 0.1-10% according to ancient surveys and 1.59% according to a 
recent Korean survey during the 2009 influenza A/(/H1N1)pdm09 pandemic [66].  Influenza and bacterial 
super-infection are two distinct clinical-pathological syndromes which have been described by Morens and 
Fauci [67].  The first with 10 to 15% fatal cases is similar to acute respiratory distress (ARDS)-like 
syndrome while the latter with poorer prognosis with 85 to 90% fatal cases manifesting as acute 
bronchopneumonia, with pathogenic bacteria cultured on autopsy [60, 62, 68] . 
 
3.4  Other viral infections and lung disease (SARS, MERS) 
 
In recent decades, previously unknown zoonotic respiratory tract infections with epidemic potential 
such as SARS and MERS emerged.  Human coronaviruses are usually classified into low and highly 
pathogenic [69]. The low pathogenic coronaviruses infect the upper respiratory tract and cause ‘flu-like’ mild 
respiratory illness, while highly pathogenic ones (SARS and MERS) predominantly infect lower airways 
often causing fatal pneumonia [69].  
 
Severe coronavirus pneumonia is often associated with rapid virus replication, massive inflammatory cell 
infiltration and elevated pro-inflammatory cytokine/chemokine responses producing acute lung injury and 
ARDS. Recent studies in experimentally infected animals strongly suggest a crucial role for virus-induced 
immune-pathological events in causing fatal pneumonia following coronavirus infection [69]. 
 
High initial viral titres in the airways, age and comorbidities (hypertension, diabetes, obesity, heart failure, 
renal failure, etc.) are associated with worse outcomes [70-74].  
SARS-CoV, which enters the human cell by the angiotensin-converting enzyme-2 (ACE2) receptor [75], 
presents usually with three phases [76]: 1) rapid viral replication with fever, cough, and other non-specific 
symptoms, disappearing in a few days; 2) high fever, hypoxemia, and progression to pneumonia-like 
symptoms, despite a progressive decline of viral replication; 3) development of ARDS in ∼20% of patients 
with mortality [77-79]. 
MERS, which enters the human cell by dipeptidyl peptidase four (DPP4) receptor [80],  usually starts with 
flu-like symptoms: fever, sore throat, non-productive cough, myalgia, shortness of breath, and dyspnoea, 
often progressing to pneumonia (ICU admission necessary) [73, 81]. It can also cause gastrointestinal 
symptoms (abdominal pain, vomiting, and diarrhoea).  
 
3.5  COVID-19 and lung disease 
 
According to a recent report from China, COVID-19, the disease caused by SARS-CoV-2, is 
characterised by three clinical patterns: absence or paucity of symptoms, mild to moderate disease, severe 
pneumonia requiring admission to ICU [82]. Dyspnoea develops after a median time of 8 days from illness 
onset, with a median time to ICU admission of 5 days. Up to 20% of the patients require the transfer to ICU 
[83, 84], with consequent overwhelming of healthcare capacity. The evidence suggests that while 25% of 
COVID-19 patients have co-morbidities including chronic obstructive pulmonary disease (COPD), diabetes 
mellitus, hypertension, coronary heart disease, cerebrovascular disease and malignancies, the proportion 
amounted to more than 90% among those who died [83-87]. In children, COVID-19 symptoms are usually 
milder with better outcome than adults [88-92]. Frequency of clinical presentations and outcome appear 
different in Europe with higher lethality compared to China, although this figure may change overtime due to 
better estimation of the total number of infections [93].  Besides virologic diagnosis, imaging by chest 
radiography, ultrasound and computer tomography (CT) are important for diagnosis and management. Main 
CT abnormalities include ground-glass opacity and consolidation [94]. The combination of CT scan findings, 
respiratory parameters (peripheral capillary oxygen saturation (SpO2) and PaO2/FiO2), and blood tests (C-
reactive proteins, lymphocyte count, LDH, triglycerides, ferritin, fibrinogen, D-dimer, IL-6) [84, 95], are 
important features to identify those at highest risk for ICU transfer. Lungs of dead COVID-19 patients 
showed oedema, proteinaceous exudate, focal reactive hyperplasia of pneumocytes with patchy 
inflammatory cellular infiltration, and multinucleated giant cells with fibroblastic plugs in airspaces [96, 97].  
A recent study reported autopsy cases contained diffuse alveolar damage, with mononuclear response (CD4+ 
aggregates) surrounding thrombosed vessels, in the presence of associated haemorrhages [98-100]. 
 
3.6  HIV and lung disease 
The spectrum of HIV-associated pulmonary diseases is broad and the lungs are one of the most 
frequently affected organ systems in HIV-infected persons regardless of age [101]. The absolute CD4 T-cell 
count,  used as a surrogate marker of immunodeficiency, is important in guiding the aetiological evaluation 
of lung infections [102]. Pulmonary TB infection and reactivation are more likely with a CD4 count of <500 
cells/mL. Opportunistic infections, Pneumocyctis jirovecii, bacterial infections, Kaposi sarcoma, and 
extrapulmonary/disseminated forms of TB occur mainly in patients with CD4 T-cell counts < 200 cells/mL. 
Cytomegalovirus (CMV) infection, Mycobacterium avium complex (MAC) and aspergillosis occur usually at 
CD4 counts < 50 cells/mL. Risk factors to consider are the geographical origin that predisposes to specific 
disease (such as TB, coccidioidomycosis, paragonimiasis and histoplasmosis), adherence to antiretroviral 
therapy, prescription of Pneumocystis jirovecii prophylaxis, and presence of comorbidities. Community-
acquired bacterial pneumonia occurs at all stages of HIV infection but is more frequent in patients with 
profound CD4 T-cell depletion and decreases with antiretroviral therapy. Community acquired pneumonia 
accounts for 35% to 50% of all hospital admission cases due to respiratory failure and is the main reason for 
ICU admission [103]. 
 
4.  TB and respiratory viral diseases 
4.1  TB and influenza 
The association of TB and influenza could be bidirectional: TB may increase the susceptibility to 
influenza and the risk of complications and influenza may increase the susceptibility to TB. The 
susceptibility to influenza appears to be greater in patients with pre-existing pulmonary disease (such as 
asthma and COPD). As a large proportion of post-TB treatment patients have long-term functional 
impairment, mainly COPD, which can be severe [104, 105], patients with such pulmonary sequelae may be 
predisposed and more susceptible to influenza infection and its complications including mortality [106]. 
Furthermore, the temporary immunosuppression induced by TB may increase the susceptibility of patients to 
influenza infection. An excess mortality associated with influenza has been described among TB patients in 
South Africa [107]. TB patients have a similar prevalence of viral and bacterial co-infection as their 
household contacts but TB patients often have more severe disease if they are co-infected [108]. 
 
As early as 1919, the occurrence of TB among patients  surviving influenza or pneumonia, but without clear 
distinction between both diseases was reported [109]. Influenza induces a temporary increase in the 
susceptibility to bacterial infections, exemplified by the frequent occurrence of bacterial pneumonia 
following viral pneumonitis  [110]. Because influenza impairs the immune response, it may be expected that 
influenza could also promote the development of active TB among patients with latent TB infection [111], 
but the occurrence of TB may occur much later than the occurrence of influenza, thus making the temporal 
association difficult to demonstrate. There was an excess mortality from pulmonary TB during the influenza 
pandemics of 1889 and 1918 in Switzerland [112].  It has also been reported that summer influenza 
epidemics in Wuhan, China, may have contributed to the increase in reported TB cases [113]. Conversely, a 
report from Thailand did not demonstrate a worse outcome for patients with concurrent influenza and TB 
[114] and another report from Indonesia did not demonstrate a correlation between antibodies against 
influenza and the presence of TB but there was an association between the level of antibody titres against 
influenza virus and the stage of TB [115]. Interestingly, influenza vaccination is reported to be a protective 
factor against TB in elderly persons in Taiwan [116].  The exact impact of concurrent influenza and TB 
remain uncertain. 
 
4.2  TB and HIV 
The interaction between TB and HIV is well known. Without anti-retroviral treatment, the risk of 
latent TB infection progressing to active TB disease in people living with HIV and AIDS (PLWHA) is 
greater than immunocompetent hosts. In PLWHA the risk of developing TB is in the order of 10% per year 
[117, 118]. This elevated risk is behind the WHO recommendation of TB screening and/or preventive 
treatment for all PLWHA [119, 120].  New regimens as short as 1 month (daily rifapentine plus isoniazid) to 
3 months (weekly rifapentine plus isoniazid) were recently recommended by WHO, and are well tolerated 
and effective [119, 120].  Important programmatic implications for collaboration between TB and HIV/AIDS 
services exist: TB services should test for HIV (allowing treatment of TB patients with anti-retrovirals and 
cotrimoxazole preventive therapy in patients with HIV-TB co-infection) and HIV/AIDS services should 
screen for latent TB infection (LTBI), using Tuberculin skin test/TST or interferon-γ release assay (IGRA), 
and initiate prompt treatment of TB or LTBI in PLWHA [119, 120]. Based on this rationale (two diseases, 
one patient) WHO promotes TB/HIV collaborative activities focused on 3 main pillars [121]: 1) establish 
TB/HIV collaborative mechanisms; 2) decrease burden of TB among PLWHA; 3) decrease burden of HIV 
among TB patients.  Moreover, testing for other infections in addition to HIV in TB clinics may be indicated 
during epidemics and pandemics. 
 
  
4.3  TB, SARS and MERS 
TB co-infection with SARS is rare. A study of 83 patients with SARS found 3 patients with TB co-
infection, where one patient with SARS subsequently developed TB, while the other two had TB and then 
developed SARS [122].  All three patients were on steroid therapy, which may have decreased viral- and/or 
TB-specific immunity and increased the risk of co-infection.  In a different cohort of 236 SARS patients, two 
were diagnosed with pulmonary TB [123].  The development of TB in the presence of SARS may be due to 
CD4 lymphopaenia during the viral infection [124], as CD4+ T-cells are crucial for TB-specific immunity 
[41, 125-129].  Lastly, one TB patient developed SARS co-infection because of a wrong admission to a 
cohort  of SARS  patients [130].  This highlights the importance of remaining vigilant to other 
communicable diseases including TB when epidemic or pandemic infections dominate media headlines 
[131].  TB with MERS Co-V coinfection is also rare. A report of 295 MERS-CoV patients found 2 TB 
patients [132], although it was unclear which the initial infection was. 
 
4.4  TB and COVID-19  
There may be interaction between COVID-19 and TB [133], but long-term observations are lacking 
[134].  Only two studies investigated the interactions so far. In the first ever cohort of 49 patients from 8 
countries COVID-19 was diagnosed before, simultaneously or after TB [135].  In the second study including 
69 patients mortality was investigated [136]. In a separate anecdotal report, Liu et al reported an increased 
prevalence of latent TB in patients with severe COVID-19 infection and concluded that infection with Mtb 
may influence the progression and outcome of COVID-19 [133]. Evidence on the interactions between TB 
and COVID-19 is needed. 
 
5.  Respiratory viral diseases and TB in the elderly, prisoners and other vulnerable groups 
The elderly (age ≥ 65 years old), prisoners and other vulnerable groups such as forced migrants may 
reside in high density communal settings which can perpetuate rapid infectious disease transmission during 
an epidemic or pandemic.  Immunosenescence is an additional risk factor in elderly [137].  
 
Clinical presentation of these infections in the elderly can be subtle, with atypical manifestation such as 
delirium, and may present with complications. SARS, and COVID-19 respiratory failure are well-
documented in the elderly [138, 139]. Conversely to influenza A (2009 H1N1)pdm09, a study of 4,962 
patients found elderly patients having less risk of respiratory failure, ICU admission or mechanical 
ventilation [140].  For TB, old age is a risk factor for active TB with poorer treatment outcomes [1, 141], 
while TB symptoms are indistinguishable from symptoms of malignancies.  Moreover, the elderly may also 
suffer from abnormal drug absorption and/or drug toxicities due to polypharmacy for comorbidities. 
Similarly, immunocompromised and pregnant women may also present with complications including 
respiratory failure when infected with pandemic H1N1 influenza, or TB [142-144].   
 
Diagnostic tests for each group depend on available resources and on accessibility, which may be limited to 
none for the homeless and the incarcerated, although there should be equity in the availability of testing and 
treatment.  The elderly may further have technical difficulties in providing quality respiratory samples for 
testing, such as for TB, when they have an impaired cough response.  A poor-quality respiratory sample 
inevitably delays diagnosis and contact tracing efforts. 
 
Treatment and management of viral infections and TB include prompt isolation of presumptive cases and of 
microbiological confirmed ones depending on available resources, or even controlled release of prisoners 
[145].  This is part of the comprehensive strategy to mitigate transmission in nursing homes for elderly, in 
refugee camps and correctional facilities [146].  Prognosis of TB, SARS and COVID-19 tend to be worse, 
with higher mortality in the elderly [77, 138, 147].  
 
6. Diagnostic challenges in viral diseases and TB 
For prompt diagnosis of viruses causing severe acute respiratory infections (SARI)[148], such as 
SARS-CoV, MERS-CoV and SARS-CoV-2 [149-152], and differentiation from other common bacterial 
infections, a strategic laboratory approach is needed. This approach requires integrating conventional 
virology assays, molecular platforms combining nucleic acid extraction and PCR or RT-PCR, and rapid 
molecular tests (RDTs) used in point-of-care (POC) minilabs (Table 1). Positive results using single or 
multiplex RDTs may lead to adequate cohorting and management of infected patients [153]. Negative results 
are often less conclusive because of a lack of sensitivity and non-standardised collection of specimens. Using 
metagenomic next-generation sequencing (mNGS), pathogens not included in the tests can be detected 
including both known and novel viruses. Genomic data gives information on virulence genes [154], 
resistance mutations and clusters using phylogenetic approaches [155, 156]. Specific antibody detection 
remains useful for seroprevalence studies in selected populations and in vaccine studies. The recurrence of 
old pathogens and emergence of new ones like SARS-CoV-2 underline the importance of worldwide virus 
surveillance systems [157]. For this purpose, developing protein microarrays to respiratory viruses’ serology 
is useful [153].  
 
Diagnosis of active TB relies on direct detection of Mtb, most often in respiratory specimens. Although 
culture remains the “gold standard” in terms of sensitivity and specificity, effective molecular assays to 
detect the Mtb DNA are also used on platforms and in POCs [158]. Moreover, these Mtb molecular assays 
can detect mutations associated with resistance, rapidly detecting multi-drug resistant (MDR-)TB strains 
resistant to rifampin and isoniazid, allowing appropriate therapies and curbing transmission of these strains 
[159].  Testing immune memory to a previous TB exposure (i.e latent TB infection), performed with the 
Mantoux test and IGRAs, cannot be used as surrogate of protection but identifies persons who have been 
previously infected and can be useful to guide the TB diagnostic algorithm [160].  
 The massive use of molecular assays to diagnose COVID-19 introduced similar molecular platforms that 
could be used for detecting pathogens in respiratory specimens. The challenge lies in sample processing and 
RNA/DNA extraction protocols, rather than cross-reactivity resulting in false-positive results. This is an 
opportunity to strengthen the diagnostic potential of microbiological laboratories, producing an invaluable 
asset to improve diagnosis against other infections including TB. At the same time, the expertise, tools and 
networks developed for TB diagnosis could aid the rapid implementation of molecular diagnosis of COVID-
19 and other viral infections.  Tests (lateral flow assay and ELISA- based) to rapidly detect the antigens in 
swabs or respiratory secretions and to determine serological evidence of recent and past infection and 
evidence of neutralizing antibodies are currently being evaluated. 
 
7.  Impact of new, potential and existing drugs for viral diseases and COVID-19 on TB therapy.  
Eighty percent of COVID-19 cases are generally mild and self-limiting and may require no 
treatment. Lacking licensed drugs for SARS-CoV-2, therapeutic approaches in severely ill patients are 
limited to supportive care and empirical use of antibiotics to prevent or treat secondary infections [84, 86, 
161, 162]. To provide active treatment for SARS-CoV-2, drugs potentially inhibiting viral replication 
(Figure 2) are of interest [163].  
TB patients with COVID-19 may require an adapted therapeutic approach compared to patients without 
COVID-19. Switching to intravenous anti-TB drugs is recommended for patients in intensive care in order to 
optimize drug exposure in critically ill patients [164]. Therapeutic solutions for COVID-19 in TB patients 
need to be considered in the perspective of anti-TB treatment.  However, more evidence ideally from clinical 
trials is necessary.  
 
7.1  Lopinavir/ritonavir (Kaletra) 
Lopinavir/ritonavir is a widely studied treatment for COVID-19 although evidence of efficacy is still 
limited [165]. In non-TB patients the combination, studied in an open label randomised controlled 
trial, did not show any virologic or clinical response compared to standard of care [166]. For the 
treatment of TB-HIV co-infected patients, lopinavir/ritonavir is not recommended in combination 
with rifampicin due to cytochrome P450 (CYP) induction. Super boosting of lopinavir/ritonavir by 
additional ritonavir in children on rifampicin-based TB treatment could be attempted as comparable 
drug exposure was achieved in situations without rifampicin [167].  Alternatively, rifabutin in a dose 
of 150 mg once daily has been used in combination with lopinavir/ritonavir [168]. 
 
  
7.2  Chloroquine phosphate, Hydroxychloroquine 
Chloroquine and hydroxychloroquine are evaluated in several clinical trials for therapy and 
prophylaxis against SARS-CoV-2 following promising in vitro results [163, 169].  In the absence of 
results from well-designed clinical studies, clinical benefit is currently unknown [170, 171]. Both 
drugs have immunomodulatory properties [172, 173]. Chloroquine has shown to reduce tumor 
necrosis factor-alpha production and receptor-mediated signaling in monocytes, which could prevent 
SARS-CoV-2 induced severe inflammatory response [174].  TB physicians should be careful when 
combining these drugs with TB drugs like moxifloxacin, bedaquiline, delamanid and clofazimine 
due to risk of increased QTc prolongation. An ongoing trial was halted due to irregular heart rates 
and increased risk of fatal heart arrhythmia [175].  The Food and Drug Administration (FDA) has 
also issued a warning on these 2 drugs [176].  In addition, rifampicin increase chloroquine CYP3A4 
and CYP2D6-mediated metabolism to desethylchloroquine and bisdesethylchloroquine [177]. It is 
unclear whether these metabolites are active against SARS-CoV-2.  
7.3  Steroids 
Intravenously administered steroids have been recommended for selected non-TB patients with 
ARDS preferably in trial setting [86, 161, 162]. However, the role of steroids to reduce ARDS in TB 
patients is limited as data of good quality to support the use of steroids outside the treatment of TB 
meningitis is scarce [164].  Evidence on the use of steroids in COVID-19 is awaited.   
 
7.4  Drug interactions 
Potential drug-drug interactions (DDI) are presented in Table 2. The summary of interactions are 
largely based on evaluations made from pharmacokinetics and toxicity profiles of drugs given alone 
and comparatively, when co-administered with other drugs in a separate study, in the absence of real 
dedicated DDI studies. The summary includes effects on drug exposure, monitoring/action and 
potential mechanisms. 
 
7.5  Immunomodulatory drugs 
To reduce the inflammatory response, inhibitors of interleukin (IL)-1 and IL-6 and JAK1/JAK 2 
inhibitor baricitinib are being studied [178, 179]. Azithromycin may be of potential interest for 
immunomodulatory effect [180], although data on its efficacy are lacking and its effect antimicrobial 
resistance should be considered. Interferons are being tested because of their stimulatory activities of 
innate antiviral responses [163].  
7.6 Novel drugs 
Antiviral candidates like azvudine, baloxavir marboxil, favipiravir, remdesivir, ribavirin and 
umifenovir are being tested for COVID-19 [163, 181-183] (Figure 2). Remdesivir is a nucleotide 
analogue showing in vitro activity against SARS-CoV-2 [183]. Remdesivir is being studied in two 
large phase 3 RCTs (NCT04252664, NCT04257656), of which one multi-centre trial conducted in 
Hubei, China in severe COVID-19 showed no difference in time to clinical improvement or 
mortality benefit [184]. Umifenovir has shown in vitro activity against SARS-CoV-1 [185] and 
improved radiological findings when added to lopinavir/ritonavir in a small RCT [186] and seems 
suitable for further development.  
 
8.  Controlling viral diseases and TB: strengths and opportunities.  
8.1   Principles of viral containment  
Globalisation, increased urbanisation resulting in large vastly populated and overcrowded cities and 
the development of fast mass transit networks and consequent ease of travelling, means that a virus can 
spread across a country or a continent in just a few hours. In the absence of a vaccine or an effective 
treatment, the tools to control a new viral infection have remained the same as during the 1918 Spanish 
influenza pandemic; namely early public health interventions designed to reduce the risk of transmission and 
spread of infection such as increased respiratory hygiene, cough etiquette and hand washing, voluntary 
isolation of infected individuals or households as well as quarantine of their contacts, followed by voluntary 
or mandatory physical distancing measures, restrictions on travel and transportation and dissemination of 
basic infection prevention and control messages and advice to the general population [93]. National 
Lockdown is an extreme measure that, while potentially reducing transmission, may also result in the 
collapse of the economy of a country. These non-pharmaceutical countermeasures aim at reducing the impact 
of COVID-19 by minimising the number of contacts that result in disease transmission and, thus, reducing 
the effective reproduction number R0 to below 1. The reduction of the number of cases during the epidemic 
peak is crucial to reduce the burden on the health care services and other related sectors and aims to flatten 
the curve by spreading cases over a longer period of time. This approach, while not necessarily reducing the 
total number of cases, gains time necessary for the development, production and distribution of effective and 
safe pharmaceuticals (i.e. vaccines and antiviral drugs), implementation of adequate hospital response and 
obtaining necessary ICU equipment as well as more sensitive diagnostic tests. 
 
Infection Control refers to the different methods and strategies deployed to reduce or prevent the incidence 
and/or transmission of infections (see section 8.2).  Containment, through early detection, investigation and 
reporting of cases, together with contact tracing with self-isolation, aimed at containing, preventing or 
delaying the spread of the disease in the community.  Geographical containment in a defined area relies on 
measures to restrict the virus spreading beyond the ‘Containment Zone’ or ‘Cordon sanitaire’, including 
pharmacological and public health interventions such as intensified surveillance and laboratory testing, 
movement restrictions in and out of the containment zone, and monitoring the area immediately surrounding 
the containment zone (buffer zone) for secondary infections [187]. 
 
Delaying the spread of infection can be achieved by early identification and treatment of cases, monitoring 
and follow-up of contacts, physical distancing measures such as proscribing public or religious gatherings, 
closing schools impacting working parents, sports events or businesses reducing the contact between people. 
It aims at lowering the epidemic peak reducing the burden of cases at a given time maintaining it below 
health care capacity. 
 
A systematic analysis of the responses to the 1918 Influenza pandemic showed that in the USA, cities that 
introduced early social isolation measures experienced a significant reduction of viral spread, approximately 
50% lower peak death rates and nearly 20% lower cumulative excess mortality than cities that did not, with a 
consequent reduction on health care pressures [188].  
8.2   Airborne infection control and workplace safety   
Airborne infection control in healthcare settings uses a hierarchy of control measures based on 
elimination of sources of infection, engineering controls, administrative controls, and personal protective 
equipment (i.e., surgical masks for infectious patients and respirators for healthcare workers and 
visitors)[189-191].  This approach is described in detail in the TB guidelines [189, 190], but can be extended 
also for viral infections including COVID-19 [192, 193].  As presently under discussion in countries under a 
post-lockdown phase perspective, the concept is valid also to ensure workplace safety in non-healthcare 
settings. 
While N95/N99 and FFP2/FFP3 respirators or higher level respirators including disposable filtering face 
piece respirators, powered air purifying respirators, elastomeric respirators (defined as per USA and 
European standards, respectively) and eye protection are recommended to protect healthcare staff and other 
exposed individuals at workplace level (after adequate training), the use of surgical masks is debated [194, 
195]. Although there is agreement on the use of surgical masks to limit the spread of droplet nuclei for 
isolated symptomatic patients, the potential mass use of surgical masks to limit the community spread of 
COVID-19 during the early stages of infection and from asymptomatic individuals is strongly discussed 
[192, 194, 195]. Arguments against their wide use are based on the false sense of protection (e.g., the 
individual feels the surgical mask protects him/her from acquiring infection) as well as the potential risks of 
moisture retention, long mask re-use, and limited filtration capacity [196].  While WHO is revising its 
recommendations, the use of masks among community members has been re-evaluated [195, 197, 198].  
Recent ECDC guidance states that face masks used by the general population may reduce the spread of the 
infection in the community by minimising the excretion of respiratory droplets from infected individuals 
who have not yet developed symptoms or who remain asymptomatic [199].  In general, all infection control 
measures are important to prevent infections and render workplaces safe. 
 
The stability of SARS-CoV-2 is similar to SARS-CoV-1 and studies indicate that aerosol and fomite 
transmission of SARS-CoV-2 is plausible [9], and can be associated with nosocomial spread and super-
spreading events since it can remain viable and infectious in aerosols for hours and on surfaces up to days 
[200].  
 
Current evidence provides support for direct contact and respiratory droplets as predominant routes of 
SARS-CoV-2 transmission [201], and highlights the importance of environmental surface cleaning with a 
hospital grade disinfectant and meticulous hand hygiene. 
 
SARS-CoV-2 is inactivated by common disinfection measures such as a 5-minute contact with household 
bleach [202]. The following disinfectants kill the virus: ice-cold acetone (90 seconds), ice-cold 
acetone/methanol mixture (40:60, 10 minutes), 70% ethanol (10 minutes), 100% ethanol (5 minutes), 
paraformaldehyde (2 minutes), and glutaraldehyde (2 minutes). Commonly used brands of hand disinfectants 
also inactivate SARS-CoV (30 seconds) [203].  The ECDC guidance on disinfection of environments in 
healthcare and non-healthcare settings potentially contaminated with SARS-CoV-2 recommends products 
with virucidal activity licensed in the national markets or 0.05% sodium hypochlorite (NaClO) (dilution 
1:100, if household bleach is used, which is usually at an initial concentration of 5%). For surfaces that can 
be damaged by sodium hypochlorite, products based on ethanol of at least 70% can be used [204].  The virus 
is sensitive to heat (60°C for 30 minutes) [203], and UV radiation (60 minutes) [205]. 
 
Outside the host, the virus can survive for 4 days in diarrheal stool samples with an alkaline pH [203],   
more than 7 days in respiratory secretions at room temperature, for at least 4 days in undiluted urine, faeces 
and human serum at room temperature[202], up to 9 days in suspension, 60 hours in soil/water, more than a 
day on hard surfaces such as glass and metal [203], up to 48 hours on plastic surfaces [206], and 6 days in 
dried state [203]. 
 
The virus does not survive well after drying on paper, but lasts longer on disposable gowns compared to 
cotton, ones [202]. Human coronavirus 229E can remain infectious on high-touch environmental surfaces 
(polyvinylchloride, laminate, wood, stainless steel) for at least 7 days at ambient temperature (24°C) and 
relative humidity conditions (~50%) [207]. 
 
The specific features of COVID-19, which spreads very rapidly with a short incubation period and infects 
exponentially thousands of individuals in all age groups [208], calls for the implementation of specific 
containment measures as discussed in section 8.1. 
 
8.3   Human resources, equipment and new approaches to clinical management 
The COVID-19 pandemic is, first and foremost, a health crisis [209].  However, it is rapidly 
becoming also an economic crisis.  In a vicious circle, the reduction in economic activities reduces money 
circulation, tax revenues and finances available for establishing the public-health countermeasures needed to 
control the pandemic.  At the same time, social protection measures to ensure a minimum salary to the many 
workers who cannot be supported by their employers increases the financial constraints at the government 
level.  The poverty generated by the economic crisis is likely to have medium and long-term consequences, 
particularly in resource-limited countries, with increase in malnutrition and poverty-related diseases which 
include TB. 
To mitigate the consequences of this or future pandemics it is important countries develop specific plans 
with adequate human and financial resources [210].  This will prevent or limit resources currently reserved 
for other purposes (e.g. for TB programmes) which then get diverted to the emergency [211], including the 
shortage of PCR reagents being used for COVID-19 diagnosis which may impact on molecular TB 
diagnosis.  Moreover, the emergency plan should be able to ensure rapid procurement and distribution of 
diagnostics, drugs, ventilators, masks, personal protective equipment and respirators needed to ensure an 
adequate response and adequate human resources [210, 212].  Telemedicine would be an important approach 
to deliver care, especially as a means to reduce the risk of cross-contamination caused by close contact [213].  
To be effective, as part of an emergency response, telehealth would require to be routinely used in the health 
system.  This would imply a change in the management and the redesign of existing models of care.  
Moreover a central system of controlling the pandemic is needed, for example in Italy, the Italian Civil 
Protection Department [214],  which is normally dedicated to seismic hazard or natural disaster assessment 
and intervention. A central system will ensure prompt coordination of the emergency response and 
implementation of the emergency plan [212]. 
 
8.4   Impact of ‘fear’ of viral infections on health services and TB services 
There are many factors affecting access to health care: affordability and physical/geographical 
accessibility are essential; socio-demographic factors (ethnicity, gender, age, marital and socioeconomic 
status) and psychological factors such as fear can significantly hinder or delay access to TB diagnosis and 
care. 
 
Fear, defined as an instinctive emotional reaction to a specific, identifiable and immediate threat such as a 
dangerous animal, infection, deportation or imprisonment has a protective function associated with defensive 
behaviours such as hiding, fight or flight responses.  Fear of TB itself, fear of discrimination – either self-
stigma or fear of being stigmatised by others, including health care providers; fear of factors associated with 
health care such as the fear that receiving a diagnosis of TB or TB treatment could affect the way they are 
perceived by society and even lead to deportation or exclusion are well recognised barriers to timely access 
to care [215]. 
 
In addition, physical distancing measures imposed to reduce the transmission of COVID-19 (SARS-CoV-2) 
such as self-quarantine, closure of all non-essential services including small clinics, movement restrictions 
and limited access to public transport, police patrol and enforced isolation measures all have a potential 
deleterious impact on access to TB care.  These factors affect all groups but disproportionately impact those 
minorities more often afflicted by TB such as migrants, refugee and asylum seekers, ethnic minorities or the 
poor.  The effect on management of non-pandemic conditions including TB, strokes and myocardial 
infections is not only because of unwillingness of individuals to attend healthcare facilities for fear of 
catching infection, but also because anything with fever may wrongly be assumed to be caused by the 
pandemic organism. 
 
9.  Lessons on COVID-19 and TB: lessons learned and common solutions  
9.1  Country response to COVID-19  
The response of European Union (EU) and European Economic Area (EEA) countries and the UK to 
the COVID-19 epidemic is provided in Table 3[216] . By 3 April 2020, 25/31 (81%) countries had closed all 
educational institutions, higher education and secondary schools, primary schools, and day-care/nurseries; in 
some countries primary schools (2/31 [6%]) and/or day-care/nurseries (6/31 [19%]) remained open.  Public 
spaces were closed in 30/31 (97%) countries, and includes closure of museums, theatres, cafes and 
restaurants, and gyms and sport facilities.  Mass gatherings have been cancelled in all 31/31 countries.  In 
some countries this means that indoor and outdoor gatherings of > 5 persons are forbidden and in others only 
larger gatherings of more than 1000 persons are banned.  Finally, more than half of EU/EEA countries and 
the UK (18/31, 58%) implemented a full national lockdown, i.e. stay-at-home orders for regions or entire 
countries.  Of the 13 countries without national lockdown, one issued stay-at-home recommendations to the 
general population, and nine issued stay-at-home recommendations for risk groups.  The assessment of the 
response shows that there has been a lack of uniformity in the implementation of different measures.  An 
analysis of the efficacy of those at the end of the emergency should guide future policies. 
 
  
9.2  TB and COVID-19: interactions  
There are multiple interactions at the different levels of prevention, diagnosis and treatment between 
the responses to TB and COVID-19 [135, 136, 217].  Similarities and differences related to infection control 
and workplaces safety have been discussed. 
 
For diagnosis, the possibility of using a platform like Xpert offers synergies, although the risk is that during 
the COVID-19 emergency the existing equipment is diverted from TB diagnosis.  Personal protective 
equipment is needed to protect laboratory personnel handling viral specimens [135, 136]. 
 
Cough is the pivotal symptom to diagnose TB. In the absence of adequate diagnostic tools, the presence of 
cough, fever and other non-specific symptoms complicates differential diagnosis of TB, COVID-19 and 
other respiratory infections [135]. 
 
The necessary physical distancing policies are likely to negatively affect active case finding as well as 
community-based activities which are important  to manage TB (and HIV) in high TB burden countries 
[217]. However, they may reduce transmission of TB, which has already been shown for influenza [218, 
219].  Both clinical and programmatic approaches to TB treatment are also affected in high–burden countries 
and drug procurement (particularly for second-line drugs) is likely to suffer as well.  
 
Last but not least, the expected major economic crisis which will follow the COVID-19 pandemic may result 
in increased poverty, social disturbances, and malnutrition with a profound impact increasing TB incidence 
and mortality [220-222].  
 
9.3   What we can and cannot learn from TB programmes in the response to COVID-19 pandemic 
Political commitment, strategic planning, community mobilisation, research and development are 
key elements in the battle against either TB or COVID-19.  While a sustainable and effective treatment 
programme is the key to successful control of TB, good pandemic preparation with adequate emergency 
response capacity is needed when confronted with viruses with pandemic potential such as SARS-CoV-2 or 
influenza.  Early and determined action to contain the COVID-19 epidemic at its localized or importation 
stage will give more time for reinforcement of care facilities, manpower and supplies [223].  Triage of 
suspects and patients according to their isolation and treatment needs will help to maximize the healthcare 
throughput with limited resources.  Simultaneous measures to contain the spread of the epidemic is necessary 
to limit the mounting patient load and avoid major breaches in nosocomial infection control and total 
collapse of the healthcare system.     
 
Breaking the transmission link is the main method for containing an infectious disease in the absence of an 
effective vaccine. Controlling a respiratory infection at source is often more cost-effective than targeting 
multiple intervention points downstream for environmental control or personal protection [224].  For TB, 
wearing a surgical mask can reduce the transmission by 56% [225].  The evidence for the protective effect of 
cloth masks is limited and contradicting [196, 226]. For both diseases, early case detection is important for 
source control, but case finding may be delayed by inconspicuous or non-specific symptoms [135]. TB can 
be stopped at source by effective treatment. Isolation for the whole infectious period is needed to contain the 
spread of COVID-19. Like TB, contact tracing may only pick up a small portion of COVID-19 cases when 
widespread local transmission occurs with unclear transmission links [227]. Physical distancing [228], and 
adjunctive use of face masks for unavoidable person-to-person contact  are then the only effective measures 
to slow the otherwise exponential growth of the COVID-19 epidemic [194].  The current physical distancing 
and stay-at-home measures due to the COVID-19 pandemic will pose challenges to TB programmes to 
provide the necessary diagnosis, treatment and care for the people and communities affected by TB. To avoid 
disruption of TB services innovative approaches (such as virtual care, digital health, and community-
monitoring solutions, etc.) will be necessary[197]. 
 
10. Consensus statements 
 
 The consensus statements derived from the Delphi process and the level of agreement achieved are 
summarised in Table 4. The ECDC PHE did not participate in the Delphi. 
 
The scores, from the 37 questionnaires received, exceeded 3 (from intermediate to highest score) in all the 18 
statements, ranging from 3.1 to 4.8 out of a maximum of 5.  The lowest scores were found for the statements 
on hydroxychloroquine/chloroquine and possible protective effect of BCG (Statements 5 and 12), where less 
evidence is available.  The highest scores were found for the statements on risk factors, outcomes and 
transmission (Statements 6 and 7) and for public health and prevention measures (Statements 13 and 14). 
 
The majority of experts scored 4 or 5 (high scores) in all statements except Statements 5 and 12. 
The Delphi process suggests the experts tended to agree on the relevance of the statements where more solid 
and high-quality evidence is available. 
 
11. Conclusions  
 
Altogether in this consensus-based document we describe the effects of epidemic and pandemic viral 
infections (SARS, MERS, influenza A(H1N1)pdm09, HIV and COVID-19) and the interactions with TB and 
the lung, the majority of these diseases are droplet-borne. The diagnostic tools range from nucleic acid 
detection and molecular techniques, to immunoassays, and traditional cultures for Mtb.  Core management 
issues were discussed, including drugs, drug-drug interactions, novel therapies, and principles of infection 
control and workplace safety. COVID-19 and TB interactions were discussed in-depth based on the scanty 
information available so far, which requires broad and in-depth research into the subject. New approaches to 
clinical management and country responses specifically to COVID-19 were elaborated by the expert panel, 
as well as opportunities and lessons for future responses.  
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Figure legend 
 
Figure 1. The lungs and gut are exposed to environmental substances and pathogens. Early protection 
response to respiratory viruses includes mucous, surfactants and antiviral peptides that can prevent initial 
attachment and viral entry.  Respiratory viruses enter via the respiratory epithelium.  Epithelial cells have a 
key role in initiating the immune response by recognizing viral components -Pathogen Associated Molecular 
Patterns (PAMPs)- via TLRs and intracellular receptors.  These cellular sensors trigger a signaling cascade 
resulting in the upregulation of Type I and III interferons and the inflammatory response.  This leads to 
differentiation of dendritic cells (DCs) that mediate the induction of the adaptive immunity, and promote the 
recruitment of innate immunity cells, in particular neutrophils and natural killer (NK) cells.  NK cells have 
the ability to kill virus-infected cells via perforin-granzyme–dependent mechanisms or by the Fas-FasL 
pathway.  Moreover, alveolar macrophages, recruited monocytes and macrophages as well as DCs, pick 
pathogen components and contribute to the immune response.  All of these cells produce cytokines and 
chemokines that are important for the establishment of the adaptive responses and of the anti-viral state.  The 
adaptive response to respiratory viruses is mediated by both T and B-cell compartments.  T-cells contribute 
to the generation of the B-cell response.  B-cells produce antibodies that may neutralise the respiratory 
viruses directly by binding to viral surface proteins that are essential for entry of the virus into host cells or 
through the ligation of Fc receptors to trigger the complement cascade and antibody-dependent cell-mediated 
cytotoxicity.  Antibodies are in the form of IgA, mainly in the upper respiratory tract, or IgG in the lower 
respiratory tract.  Viral clearance is also mediated by CD8+-specific T-cells with cytolytic activity.  
Protective anti-viral T-cell response is mainly mediated by the IFN-γ production and is therefore biased 
toward a Th-1 response whereas other T-cell subsets as Th2 cells and Th17 cells play a minor role and they 
may be responsible for lung tissue damage. Moreover, regulatory mechanisms adopted by T-cells such as IL-
10 secretion, or upregulation of inhibitory receptors such as programmed cell death protein 1 (PD-1) or 
expansion of the T-regulatory cell subsets work to balance tissue damage and viral clearance. 
 
Figure 2. Proposed mechanism of action of drugs used for SARS-CoV-2. SARS-CoV-2 can enter the cell 
through ACE2 and TMPRSS2.  Camostat mesylate acts as an inhibitor of TMPRSS2 and umifenovir can 
inhibit the viral entry to the cell [181, 229, 230].  Chloroquine, hydroxychloroquine and baricitinib 
mechanism of action is not fully understood, however it is proposed that these drugs affect the viral entry.  
Baricitinib also inhibits the AP-2-associated protein kinase [174, 181, 231].  Lopinavir/ritonavir and ASC-
09/ritonavir as protease inhibitors inhibit the proteolysis.  Lopinavir/ritonavir inhibits specifically the 
proteinase 3CLpro [232].  Ribavirin and favipiravir both have wide antiviral activity and have the potential 
to inhibit SARS-CoV-2 RNA replication [233-235].  Azvudine, a nucleoside reverse transcriptase inhibitor, 
also inhibits the RNA replication [236].  A probable mechanism of action for baloxavir marboxil is the 
inhibition of transcription through inhibiting cap-dependent endonuclease [237].  Favipiravir and remdesivir, 
inhibit the RNA-dependent RNA polymerase, which results in reducing RNA synthesis [181, 234, 235, 238].   
Table 1: Performance characteristics of diagnostic approaches to respiratory infection 
Abbreviations: NAAT: Nucleic Acid Amplification Tests; POCT: Point of Care Test; NGS: Next Generation Sequencing; WGS: whole genome sequencing; NA: Not 
applicable; NRU: Not routinely used; ES: Experimental settings only.
1
IFA: Immunofluorescence microscopy on respiratory samples to detect the most common viruses; 
ZN/AR: Ziehl-Neelsen or Auramine/Rhodamine staining to detect acid fast bacilli; 
2
Viral culture are established in several eukaryotic cell lines. Mycobacterial culture in 
liquid or solid media; 
3
The only approved POCT Ag for TB detects LAM in urine samples and has been licensed to diagnose TB in HIV-infected patients and to monitor 
therapy; 
4
 Mantoux test; Quantitation: - very poor; + poor; ++:  good; +++: excellent. *Considering only the time of the procedure: less than 2 hours. 
  
    
  Respiratory viruses M. tuberculosis complex 
 
  
Sensitivity Specificity 
Time 
to 
result* 
User-
friendly 
Unknown 
or 
uncommon 
viruses 
Sensitivity Specificity 
Time 
saving 
User-
friendly 
Drug 
susceptibility 
testing 
Molecular 
diagnosis 
Manual NAAT +++ +++ - - - +++ ++ + - + 
Automated 
NAAT 
+++ +++ + + - +++ +++ ++ ++ ++ 
POCT-NAAT + ++ +++ +++ - +++ +++ +++ + + 
NGS 
(metagenomics 
and WGS)  
- - - - ++ + +++ - - +++ 
Microscopy IFA or ZN/AR
1
 - ++ - - - + + ++ + - 
Culture
2
  - + - - + +++ +++ - - +++ 
Antigen Detection  
POCT Ag - + +++ ++ - +
3
 ++ +++ +++ NA 
ELISA ++ ++ - - - NA NA NA NA NA 
Immunodiagnosis Serology NRU NRU - - - 
Not 
recommended 
Not 
recommended  
NRU NRU NA 
 
IFN release 
assays 
ES ES - - - ++ + ++ + NA 
 Skin test
4
 
NA NA NA NA NA 
++ + ++ ++ NA 
            
Table 2. Drug interactions between TB and potential COVID-19 medications. 
 
 WHO First line TB drugs Second line TB drugs: 
Group A 
 
Group B 
                                                                                                         
Group C 
 INH RIF EMB PZA 
 
LFX MFX BDQ LZD CFZ Cs DLM IMI/ 
CIS 
MEM AMI STR ETO PTO PAS 
Antivirals 
Atazanavir  
[239] 
—  X 
   
— — 
    
— ♥ 
  
  ♥ 
  
  ♥ 
 
— — ♥ 
 
—   ♥ 
 
— — — — — — — 
Baloxavir 
marboxil [240] 
—  Xa 
 
— — — — ∆c  
 
— ∆d 
 
— ∆c 
 
— — — — — — — 
Favipiravir  
[241, 242] 
— 
 
— 
 
— 
 
— 
U 
— — — — — — — — — — — — — — 
Galidesivir n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
Lopinavir/ 
Ritonavir [243, 
244] 
— 
 
 X 
 
— — — ♥   ♥ 
 
  ♥ 
 
— — ♥ —   ♥ 
 
— — — — — — — 
Oseltamivir  
 
— — — — — — — — — — — — — ∆e 
 
∆e — — — 
Remdesivir  
[243] 
—  X — — — — — — — — — — — — — — — — 
Ribavirin  
[243] 
— — — — — — — —    — — — — — — — — — — 
Umifenovir     
[245, 246] 
— 
 
 Xa   
 
— — — ∆b  
 
∆c  
 
— ∆d 
 
— ∆c 
 
— — — — — — — 
Antibacterials 
Azithromycin 
[247] 
— 
 
— — — —  ♥ —  ♥ —  ♥ — — ♥ — —  ♥ — — — — — — — 
Antiprotozoal 
Chloroquine 
[248-250] 
— 
 
 X — — —♥ — ♥ — ♥ — — ♥ —  — ♥ —  
      
—  
      
—   
     
—   
      
— — — 
Nitazoxanide — — — —  — — — — — — — — — — — — — — 
Immunomodulating drugs 
Anakinra — — — —  — — — — — — — — — — — — — — 
Baricitinib — — — —  — — — — — — — — — — — — — — 
Hydroxychloro-
quine [248, 251] 
— 
 
 X — — — ♥ — ♥  — ♥ — — ♥ — —♥ —  
      
—  
      
— — — — — 
Interferons 
[252-254] 
— — — 
 
— 
 
— ♥ 
      
— ♥ 
     
— ♥ 
        
— 
 
— ♥ 
 
— 
 
—  ♥ 
 
—  
    
—  
   
—   —   
 
— 
 
— 
 
— 
 
Tocilizumab  
[243, 255] 
— 
 
— — — — — — —    
 
— — — — — — — — — — 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interaction symbols: 
       decreased exposure to the TB drug + Action required (action: dose adjustment or monitoring). 
       increased exposure to the TB drug + Action required 
decreased exposure to the COVID-19 drug + Action required. 
increased exposure to the COVID-19 drug + Action required. 
— no significant interaction predicted based on metabolic pathway (does not mean absence of interaction). 
∆ possible interaction based on metabolism and clearance, but no specific data available. 
n/a   no available pharmacokinetic data. 
 
Monitoring/action symbols: 
♥   requires ECG monitoring due to the risk of QT and/or PR prolongation, or other cardiac abnormalities. 
  requires full blood count (FBC) monitoring 
U  uric acid monitoring 
 monitor for potential seizures (rare) 
     monitor for ototoxicity 
X  should not be administered together. 
 
Mechanism symbols: 
 Cytochrome P450 mediated mechanism 
 UGT enzyme-mediated glucuronidation  
 
Additional information: 
a. recommended based on predicted interaction. 
b. UGT 1A1 is involved in moxifloxacin metabolism and could be involved in umifenovir metabolism (mainly UGT 1A9). 
c. Both drugs are metabolized by CYP3A4. 
d. CYP3A4 is involved in the metabolism of baloxavir (minor extent) and umifenovir, and clofazimine is a CYP3A4 inhibitor. 
e. both drugs primarily undergo renal excretion. 
 
Abbreviations: 
WHO: World Health Organization, INH: isoniazid, RIF: rifampicin, EMB: ethambutol, PZA: pyrazinamide, LFX: levofloxacin, MFX: moxifloxacin, BDQ: bedaquiline, LZD: linezolid, CFZ: 
clofazimine, Cs: cycloserine, DLM: delamanid, IMI/CIS: imipenem/cilastin, MEM: meropenem, AMI: amikacin, STR: streptomycin, ETO: ethionamide, PTO: prothionamide, PAS: p-
aminosalicylic acid, LPV/r: lopinavir/ritonavir, HCLQ: hydroxychloroquine, CLQ: chloroquine, RDV: remdesivir 
 
 
 
 
 
Table 3: Response measures undertaken in EU/EEA Member States and the UK at the 
national level as of 3 April 2020* 
 
* The data on response measures are based on information available from official public sources as of 
Friday 3 April 2020 at 18:00 and may not capture measures being taken by countries that are not 
reported on publicly available websites. The situation is evolving rapidly and this represents a 
  
Closure of educational 
institutions 
Closure 
of public 
spaces 
Mass 
gathering 
cancellations 
Stay-at-
home order 
(enforced) 
Stay-at-home 
recommendation 
(general 
population) 
Stay-at-home 
recommendation 
(risk group)  
  Higher 
education/ 
Secondary 
School 
Primary 
School 
Day-care 
or nursery    
  
Austria X X X X X X X  
Belgium X X  X X X   
Bulgaria X X X X X   X 
Croatia X X X X X    
Cyprus X X X X X X   
Czech 
Republic 
X X X X X X   
Denmark X X X X X   X 
Estonia X X  X X X   
Finland X X  X X   X 
France X X X X X X   
Germany X X X X X   X 
Greece X X X X X X X  
Hungary X X X X X    
Iceland X   X X   X 
Ireland X X X X X X X X 
Italy X X X X X X  X 
Latvia X X  X X X   
Liechtenstein X X X X X  X X 
Lithuania X X X X X    
Luxembourg X X X X X X  X 
Malta X X X X X   X 
Netherlands X X X X X X  X 
Norway X X X X X   X 
Poland X X X X X X   
Portugal X X X X X X  X 
Romania X X X X X X  X 
Slovakia X X X X X    
Slovenia X X X X X X   
Spain X X X X X X X X 
Sweden X    X   X 
United 
Kingdom 
X X X X X X X X 
snapshot of the measures that countries in the EU/EEA and the UK have reported to date. The 
response measures displayed are national measures, reported on official public websites. Response 
measures collected include: mass gathering cancellations (for specific events or a ban on gatherings of 
a particular size); closure of public spaces (including restaurants, entertainment venues, non-essential 
shops and so on); closure of educational institutions (including day-care or nursery, primary schools, 
and secondary schools and higher education); stay-at-home recommendations for risk groups or 
vulnerable populations (such as the elderly, people with underlying health conditions, physically 
disabled people etc.); stay-at-home recommendations for the general population (which are voluntary 
or not enforced); and stay-at-home orders for the general population (these are enforced and also 
referred to as ‘lockdown’). The data on response measures has several limitations. Firstly, there is 
substantial heterogeneity in physical distancing policies and their implementation between countries. 
For instance, the level of enforcement of measures may vary between countries and there may be 
specific rules and exceptions to the measures, making interpretation of the data challenging. The 
measures displayed in these figures are measures reported at national level and it should be noted that 
due to the evolution of the outbreak in certain regions, regional or local measures often preceded 
national ones. The exact dates of introduction were often available from official sources but delays in 
their implementation may have occurred. Additionally, availability of public data from official 
government sources varies among countries. For some countries, data are no longer available on 
official websites concerning measures that are no longer in force, which may result in the data for 
more recent measures being more complete.  
Table 4. Consensus statements derived from the Delphi process 
Consensus statements 
1 (lowest 
relevance) 
2 3 4 
5 (highest 
relevance) Mean 
(SD) 
n (%) 
1. Large droplets increase the risk of 
respiratory viral infection through direct 
transmission. 
0 (0.0) 6 (16.2) 6 (16.2) 10 (27.0) 15 (40.5) 3.9 (1.1) 
2. Respiratory viral infections are more 
likely to occur in older patients (with or 
without comorbidities) and infants. 
1 (2.7) 5 (13.5) 10 (27.0) 12 (32.4) 9 (24.3) 3.6 (1.1) 
3. Elderly patients are more likely to 
develop acute respiratory distress 
syndrome and there is an age-related 
death risk. 
0 (0.0) 0 (0.0) 4 (10.8) 10 (27.0) 23 (62.2) 4.5 (0.7) 
4. Antibodies might neutralize 
respiratory viruses and, then, decrease the 
risk of recurrent infections. 
0 (0.0) 4 (10.8) 7 (18.9) 17 (46.0) 9 (24.3) 3.8 (0.9) 
5. BCG-vaccination might offer 
protection against COVID-19. RCTS 
are needed. 
4 (10.8) 7 (18.9) 10 (27.0) 10 (27.0) 6 (16.2) 3.2 (1.2) 
6. Severe COVID-19 is associated with 
rapid virus replication, massive 
inflammatory cell infiltration in the lung, 
and elevated pro-inflammatory 
cytokine/chemokine response. 
0 (0.0) 0 (0.0) 1 (2.7) 7 (18.9) 29 (78.4) 4.8 (0.5) 
7. High initial SARS-CoV-2 load in 
the airways, older age (≥65 years), and 
comorbidities of the infected individual are 
associated with worse COVID-19 
outcome and thus patients with these risk 
factors need close attention. 
0 (0.0) 0 (0.0) 3 (8.1) 7 (18.9) 27 (73.0) 4.7 (0.6) 
8. The combination of CT scan findings 
(ground-glass opacity and consolidation), 
clinical presentation respiratory 
parameters (peripheral capillary oxygen 
saturation (SpO2) and PaO2/FiO2 ), 
and blood tests (C-reactive proteins, 
lymphocyte number, fibrinogen, D-dimers, 
IL-6 ) helps identifying COVID-19 
patients at highest risk for ICU transfer. 
0 (0.0) 1 (2.7) 0 (0.0) 10 (27.0) 26 (70.3) 4.6 (0.6) 
9. CD4 T-cell counts is key to guide the 
aetiological evaluation of lung infections in 
HIV-infected individuals. 
0 (0.0) 3 (8.1) 7 (18.9) 18 (48.7) 9 (24.3) 3.9 (0.9) 
10. Temporary immunosuppression 
induced by TB might increase the 
susceptibility to influenza viruses. 
2 (5.4) 6 (16.2) 8 (21.6) 18 (32.5) 9 (24.3) 3.5 (1.2) 
11. An excess mortality associated with 
influenza is found among TB patients. 
1 (2.7) 5 (13.5) 8 (21.6) 15 (40.5) 8 (21.6) 3.7 (1.1) 
12. Chloroquine and hydroxychloroquine 
have potential to improve the treatment 
success rate of COVID-19 patients. 
RCTS are needed. 
4 (10.8) 8 (21.6) 10 (27.0) 9 (24.3) 6 (16.2) 3.1 (1.3) 
13. Public and social distancing reduce 
the risk of SARS-CoV-2 transmission. 
0 (0.0) 0 (0.0) 3 (8.1) 6 (16.2) 28 (75.7) 4.7 (0.6) 
14. Appropriate use of facial masks 
(surgical masks in the general population; 
N95 for HCWs performing aerosol-
0 (0.0) 0 (0.0) 1 (2.7) 9 (24.3) 27 (73.0) 4.7 (0.5) 
producing activities) on symptomatic 
patients and their contacts can reduce the 
risk of SARS-CoV-2 infection by 
limiting the spread of droplet nuclei from 
isolated symptomatic patients. 
15. SARS-CoV-2 virus remain 
infectious in the environment on different 
surfaces for days. 
0 (0.0) 5 (13.5) 7 (18.9) 5 (13.5) 20 (54.1) 4.1 (1.1) 
16. Social protection measures and 
specific national centralized emergency 
plans can reduce the healthcare and socio-
economic burden of respiratory viral 
infections resulting in 
epidemics/pandemics. 
0 (0.0) 0 (0.0) 4 (10.8) 14 (37.8) 19 (51.4) 4.4 (0.7) 
17. Stigma and social discrimination 
affect all virus-infected population groups 
but disproportionately the minorities. 
0 (0.0) 5 (13.5) 7 (18.9) 12 (32.4) 13 (35.1) 3.9 (1.1) 
18. Late implementation of national 
lockdown can itself alone be effective in 
reducing the burden of COVID-19 but 
it has serious impact on the society and 
the economy. 
3 (8.1) 3 (8.1) 6 (16.2) 8 (21.6) 17 (46.0) 3.9 (1.3) 
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